Abstract
Aim: The present study was conducted to evaluate the corelation between Fibrosis-4 score (FIB-4) in cases of Liver fibrosis as well as Liver steatosis in comparison to other liver fibrosis assessment scores.
Methodology: Cross-sectional study was conducted amongst 352 participants who had type 2 diabetes mellitus (T2DM). FIB-4 score and Non-alcoholic fatty liver disease fibrosis score (NFS) were calculated using blood parameters and Liver Stiffness Measurement (LSM) scores along with Controlled attenuation parameter (CAP) scores were calculated using Vibration Controlled Transient Elastography (VCTE). Spearman’s correlation estimates were used to evaluate these fibrosis scores of FIB-4, NFS and LSM in Metabolic dysfunction associated steatotic liver disease (MASLD) patients.
Results: Out of a total cohort of 352 persons, 75% had steatosis and 27.1% had fibrosis based on the findings of VCTE. According to prediction based on FIB- 4, 10.8% had fibrosis, and based on the NFS fibrosis score 23.4% had fibrosis. Our data revealed a positive correlation between the FIB-4 score and LSM by VCTE (r = 0.22, p < 0.001).
Conclusion: Beyond its risk assessment, FIB-4 serves as a prognostic biomarker with clinical significance. This straightforward scoring system can act as an early warning signal, helping to identify patients who are at risk for advanced liver fibrosis and may need referral to specialized medical care.
Keywords
- Chronic liver disease
- liver fibrosis
- MASLD
- screening
- fibrosis 4 score.